# Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib

> **NCT05007093** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Yansong Lin** · enrollment: 20 (actual)

## Conditions studied

- DTC - Differentiated Thyroid Cancer

## Interventions

- **DRUG:** Anlotinib hydrochloride

## Key facts

- **NCT ID:** NCT05007093
- **Lead sponsor:** Yansong Lin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-01
- **Primary completion:** 2024-11-01
- **Final completion:** 2025-06-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05007093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05007093, "Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05007093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*